T. Sørlie, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc. Natl Acad. Sci. USA 98, pp.10869-10874, 2001.
DOI : 10.1002/(SICI)1096-9896(199605)179:1<31::AID-PATH523>3.0.CO;2-O

A. Prat, Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer, JNCI: Journal of the National Cancer Institute, vol.106, issue.8, p.152, 2014.
DOI : 10.1093/jnci/dju152

D. J. Slamon, Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, New England Journal of Medicine, vol.344, issue.11, pp.783-792, 2001.
DOI : 10.1056/NEJM200103153441101

M. Marty, Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2???Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group, Journal of Clinical Oncology, vol.23, issue.19, pp.4265-4274, 2005.
DOI : 10.1200/JCO.2005.04.173

E. H. Romond, Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer, New England Journal of Medicine, vol.353, issue.16, pp.1673-1684, 2005.
DOI : 10.1056/NEJMoa052122

M. J. Piccart-gebhart, Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer, New England Journal of Medicine, vol.353, issue.16, pp.1659-1672, 2005.
DOI : 10.1056/NEJMoa052306

M. Piccart-gebhart, Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2???Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial, Journal of Clinical Oncology, vol.34, issue.10, pp.1034-1042, 2014.
DOI : 10.1200/JCO.2015.62.1797

G. Von-minckwitz, Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes, Journal of Clinical Oncology, vol.30, issue.15, pp.1796-1804, 2012.
DOI : 10.1200/JCO.2011.38.8595

C. Denkert, HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer, Breast Cancer Research, vol.13, issue.1, p.11, 2013.
DOI : 10.1016/S1470-2045(11)70336-9

P. Cortazar, Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, The Lancet, vol.384, issue.9938, pp.164-172, 2014.
DOI : 10.1016/S0140-6736(13)62422-8

L. A. Carey, Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib, Journal of Clinical Oncology, vol.34, issue.6, pp.542-549, 2015.
DOI : 10.1200/JCO.2015.62.1268

F. J. Esteva, PTEN, PIK3CA, p-AKT, and p-p70S6K Status, The American Journal of Pathology, vol.177, issue.4, pp.1647-1656, 2010.
DOI : 10.2353/ajpath.2010.090885

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947262

J. D. Jensen, PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab, Annals of Oncology, vol.23, issue.8, pp.2034-2042, 2012.
DOI : 10.1093/annonc/mdr546

J. Baselga, Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2???Positive, First-Line Metastatic Breast Cancer, Journal of Clinical Oncology, vol.32, issue.33, pp.3753-3761, 2014.
DOI : 10.1200/JCO.2013.54.5384

S. Loibl, Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti???Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer, Journal of Clinical Oncology, vol.32, issue.29, pp.3212-3220, 2014.
DOI : 10.1200/JCO.2014.55.7876

I. J. Majewski, Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2???Targeted Therapies in Breast Cancer, Journal of Clinical Oncology, vol.33, issue.12, pp.1334-1339, 2015.
DOI : 10.1200/JCO.2014.55.2158

A. Rody, T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers, Breast Cancer Research, vol.10, issue.2, p.15, 2009.
DOI : 10.1186/bcr2124

G. Bianchini, Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial, Annals of Oncology, vol.26, pp.2429-2436, 2015.
DOI : 10.1093/annonc/mdv395

X. Pivot, G. Romieu, M. Debled, J. Pierga, and P. Kerbrat, 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial, The Lancet Oncology, vol.14, issue.8, pp.741-748, 2013.
DOI : 10.1016/S1470-2045(13)70225-0

A. Kramar, Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial, Annals of Oncology, vol.25, issue.8, pp.1563-1570, 2014.
DOI : 10.1093/annonc/mdu177

A. C. Wolff, American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer, Journal of Clinical Oncology, vol.25, issue.1, pp.118-145, 2007.
DOI : 10.1200/JCO.2006.09.2775

C. Curtis, Supplemental information: the genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups, Nature, vol.486, pp.346-352, 2012.

J. S. Parker, Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes, Journal of Clinical Oncology, vol.27, issue.8, pp.1160-1167, 2009.
DOI : 10.1200/JCO.2008.18.1370

M. Guedj, A refined molecular taxonomy of breast cancer, Oncogene, vol.10, issue.9, pp.1196-1206, 2011.
DOI : 10.1038/nature09515

URL : https://hal.archives-ouvertes.fr/inserm-00611752

E. Lim, Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers, Nature Medicine, vol.5, issue.8, pp.907-913, 2009.
DOI : 10.4049/jimmunol.174.10.6477

P. J. Stephens, The landscape of cancer genes and mutational processes in breast cancer, Nature, vol.135, pp.400-404, 2012.
DOI : 10.2307/2344614

S. Nik-zainal, Mutational Processes Molding the Genomes of 21 Breast Cancers, Cell, vol.149, issue.5, pp.979-993, 2012.
DOI : 10.1016/j.cell.2012.04.024

A. Langerød, Gene expression profiles and the TP53 mutation status are powerful prognostic markers of breast cancer, Breast Cancer Research, vol.7, issue.S2, p.30, 2007.
DOI : 10.1186/bcr1174

L. Silwal-pandit, TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance, Clinical Cancer Research, vol.20, issue.13, pp.3569-3580, 2014.
DOI : 10.1158/1078-0432.CCR-13-2943

R. K. Kancha, Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib, PLoS ONE, vol.6, issue.10, p.26760, 2011.
DOI : 10.1371/journal.pone.0026760.s007

D. Perera, OncoCis: annotation of cis-regulatory mutations in cancer, Genome Biol, vol.15, p.485, 2014.

J. Staaf, High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer, Breast Cancer Research, vol.10, issue.3, p.25, 2010.
DOI : 10.1186/bcr2124

F. Sircoulomb, Genome profiling of ERBB2-amplified breast cancers, BMC Cancer, vol.61, issue.1, p.539, 2010.
DOI : 10.1136/jcp.2007.052431

J. Hicks, Novel patterns of genome rearrangement and their association with survival in breast cancer, Genome Research, vol.16, issue.12, pp.1465-1479, 2006.
DOI : 10.1101/gr.5460106

L. Yang, Diverse Mechanisms of Somatic Structural Variations in Human Cancer Genomes, Cell, vol.153, issue.4, pp.919-929, 2013.
DOI : 10.1016/j.cell.2013.04.010

T. Popova, Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation, Cancer Research, vol.72, issue.21, pp.5454-5462, 2012.
DOI : 10.1158/0008-5472.CAN-12-1470

B. Mcclintock, The stability of broken ends of chromosomes in Zea Mays, Genetics, vol.26, pp.234-282, 1941.

G. R. Bignell, Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution, Genome Research, vol.17, issue.9, pp.1296-1303, 2007.
DOI : 10.1101/gr.6522707

P. J. Campbell, The patterns and dynamics of genomic instability in metastatic pancreatic cancer, Nature, vol.22, issue.7319, pp.1109-1113, 2010.
DOI : 10.1038/nature09460

M. Marotta, A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications, Breast Cancer Research, vol.42, issue.Suppl 2, p.150, 2012.
DOI : 10.1038/ng.669

S. Zakov, M. Kinsella, and V. Bafna, An algorithmic approach for breakagefusion-bridge detection in tumor genomes, Proc. Natl Acad. Sci. USA, pp.5546-5551, 2013.

C. D. Greenman, S. L. Cooke, J. Marshall, M. R. Stratton, and P. J. Campbell, Modeling the evolution space of breakage fusion bridge cycles with a stochastic folding process, Journal of Mathematical Biology, vol.110, issue.14, pp.47-86, 2015.
DOI : 10.1007/978-3-319-05269-4_32

J. Z. Sanborn, Double Minute Chromosomes in Glioblastoma Multiforme Are Revealed by Precise Reconstruction of Oncogenic Amplicons, Cancer Research, vol.73, issue.19, pp.6036-6045, 2013.
DOI : 10.1158/0008-5472.CAN-13-0186

B. M. Bolstad, R. A. Irizarry, M. Astrand, and T. P. Speed, A comparison of normalization methods for high density oligonucleotide array data based on variance and bias, Bioinformatics, vol.19, issue.2, pp.185-193, 2003.
DOI : 10.1093/bioinformatics/19.2.185

L. Gautier, L. Cope, B. M. Bolstad, and R. A. Irizarry, affy--analysis of Affymetrix GeneChip data at the probe level, Bioinformatics, vol.20, issue.3, pp.307-315, 2004.
DOI : 10.1093/bioinformatics/btg405

T. Sørlie, The importance of gene-centring microarray data, The Lancet Oncology, vol.11, issue.8, pp.719-720, 2010.
DOI : 10.1016/S1470-2045(10)70174-1

D. M. Gendoo, Computation of Gene Expression-Based Signatures in Breast Cancer. R package version 2.5.2, 2015.

R. Simon and A. Lam, BRB Array Tools Users Guide Technical Reports Biometric Research Branch, National Cancer Institute, 2006.

M. J. Dunning, M. L. Smith, M. E. Ritchie, and S. Tavaré, beadarray: R classes and methods for Illumina bead-based data, Bioinformatics, vol.23, issue.16, pp.2183-2184, 2007.
DOI : 10.1093/bioinformatics/btm311

Q. Li, N. J. Birkbak, B. Gyorffy, Z. Szallasi, and A. C. Eklund, Jetset: selecting the optimal microarray probe set to represent a gene, BMC Bioinformatics, vol.12, issue.1, p.474, 2011.
DOI : 10.1186/1471-2105-12-474

D. A. Barbie, Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1, Nature, vol.98, issue.7269, pp.108-112, 2009.
DOI : 10.4049/jimmunol.167.9.4948

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783335

J. Staaf, Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios, BMC Bioinformatics, vol.9, issue.1, p.409, 2008.
DOI : 10.1186/1471-2105-9-409

T. Popova, Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays, Genome Biology, vol.10, issue.11, p.128, 2009.
DOI : 10.1186/gb-2009-10-11-r128

URL : https://hal.archives-ouvertes.fr/inserm-00663915

P. Van-loo, Analyzing cancer samples with SNP arrays, Methods Mol. Biol, vol.802, pp.57-72, 2012.

H. Li and R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler transform, Bioinformatics, vol.25, issue.14, pp.1754-1760, 2009.
DOI : 10.1093/bioinformatics/btp324

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2705234

A. Mckenna, The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data, Genome Research, vol.20, issue.9, pp.1297-1303, 2010.
DOI : 10.1101/gr.107524.110

K. Cibulskis, Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples, Nature Biotechnology, vol.27, issue.3, pp.213-219, 2013.
DOI : 10.1093/bioinformatics/btr446

W. Mclaren, Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor, Bioinformatics, vol.26, issue.16, pp.2069-2070, 2010.
DOI : 10.1093/bioinformatics/btq330

R. Andersson, An atlas of active enhancers across human cell types and tissues, Nature, vol.45, issue.7493, pp.455-461, 2014.
DOI : 10.1093/bioinformatics/btq033

Y. Benjamini and T. P. Speed, Summarizing and correcting the GC content bias in high-throughput sequencing, Nucleic Acids Research, vol.40, issue.10, p.72, 2012.
DOI : 10.1093/nar/gks001

T. Derrien, Fast Computation and Applications of Genome Mappability, PLoS ONE, vol.39, issue.Suppl 1, p.30377, 2012.
DOI : 10.1371/journal.pone.0030377.t002

URL : https://hal.archives-ouvertes.fr/inserm-00664289

S. Zakov and V. Bafna, Reconstructing Breakage Fusion Bridge Architectures Using Noisy Copy Numbers, Journal of Computational Biology, vol.22, issue.6, pp.577-594, 2015.
DOI : 10.1089/cmb.2014.0166

C. D. Greenman, Estimation of rearrangement phylogeny for cancer genomes, Genome Research, vol.22, issue.2, pp.346-361, 2012.
DOI : 10.1101/gr.118414.110

M. Greenacre and J. Blasius, Multiple Correspondence Analysis and Related Methods, 2006.
DOI : 10.1201/9781420011319

J. Thioulouse, D. Chessel, S. Dolédec, and J. M. Olivier, ADE-4: a multivariate analysis and graphical display software, Statistics and Computing, vol.7, issue.1, pp.75-83, 1997.
DOI : 10.1023/A:1018513530268

URL : https://hal.archives-ouvertes.fr/hal-00434994

J. P. Benzécri, Sur le calcul des taux d'inertie dans l'analyse d'un questionnaire, pp.377-378, 1979.

D. L. Hoffman and J. De-leeuw, Interpreting multiple correspondence analysis as a multidimensional scaling method, Marketing Letters, vol.25, issue.3, pp.259-272, 1992.
DOI : 10.1007/BF00994134